$3396 | SAVE $599 | Single User
$6792 | SAVE $1,198 | Site License
$10187 | SAVE $1,798 | Global License

Ulcerative Colitis - Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029
[Lowest Price Guaranteed: $3,396]

Published by Global Data: 19 Oct 2020 | 274554 | In Stock
Related Topics: Ulcerative Colitis

Introduction

Ulcerative Colitis - Epidemiology Forecast to 2029

Summary

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn’s and Colitis Foundation of America, 2014; Crohn’s and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women.

GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and population-based studies to build the forecast for the diagnosed incident cases, total prevalent cases, and diagnosed prevalent cases of UC in the 8MM. GlobalData epidemiologists applied the incidence and prevalence of UC drawn from the above sources to each country’s population to calculate the number of estimated diagnosed incident cases, total prevalent cases, and diagnosed prevalent cases for UC.

The following data describes the epidemiology of UC. In the 8MM, the diagnosed incident cases are expected to increase from 157,327 cases in 2019 to 178,752 cases in 2029, at an Annual Growth Rate (AGR) of 1.36%. In the 8MM, the diagnosed prevalent cases of UC are expected to increase from 1,686,605 cases in 2019 to 2,026,976 cases in 2029, at an AGR of 2.02%. In 2029, the US will have the highest number of diagnosed prevalent cases of UC in the 8MM with 872,999 diagnosed prevalent cases, whereas Canada will have the lowest number with 86,990 diagnosed prevalent cases in 2029. In the 8MM, the total prevalent cases of UC are expected to increase from 2,031,327 cases in 2019 to 2,441,651 cases in 2029, at an AGR of 2.02%.

Scope

- The Ulcerative Colitis Epidemiology Report provides an overview of the risk factors and global trends of ulcerative colitis (UC) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).

- The report includes a 10-year epidemiology forecast for the diagnosed incident cases, diagnosed prevalent cases of UC, and total prevalent cases of UC. The diagnosed incident cases and total prevalent cases of UC are segmented by age (for all ages), and sex. The diagnosed prevalent cases of UC are segmented by age (for all ages), sex, and severity. Additionally the model provides post-operative UC cases among diagnosed prevalent cases of UC for the forecast period.

- The UC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The UC Epidemiology series will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global UC markets.

- Quantify patient populations in the global UC markets to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for UC therapeutics in each of the markets covered.

- Understand magnitude of UC population by its severity.

Table of Contents
for Ulcerative Colitis - Epidemiology Forecast to 2029

  • 1 Table of Contents

    1.1 List of Tables

    1.2 List of Figures

    2 Ulcerative Colitis: Executive Summary

    2.1 Catalyst

    2.2 Related Reports

    2.3 Upcoming Reports

    3 Epidemiology

    3.1 Disease Background

    3.2 Risk Factors and Comorbidities

    3.3 Global and Historical Trends

    3.4 Forecast Methodology

    3.4.1 Sources

    3.4.2 Forecast Assumptions and Methods

    3.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of UC

    3.4.4 Forecast Assumptions and Methods: Total and Diagnosed Prevalent Cases of UC

    3.4.5 Germany

    3.4.6 Italy

    3.4.7 Spain

    3.4.8 UK

    3.4.9 Japan

    3.4.10 Canada

    3.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of UC by severity

    3.4.12 8MM

    3.4.13 Forecast Assumptions and Methods: Post-operative UC Cases

    3.5 Epidemiological Forecast for UC (2019-2029)

    3.5.1 Diagnosed Incident Cases of UC

    3.5.2 Age-Specific Diagnosed Incident Cases of UC

    3.5.3 Sex-Specific Diagnosed Incident Cases of UC

    3.5.4 Diagnosed Prevalent Cases of UC

    3.5.5 Age-Specific Diagnosed Prevalent Cases of UC

    3.5.6 Sex-Specific Diagnosed Prevalent Cases of UC

    3.5.7 Diagnosed Prevalent Cases of UC by Severity for Ages <18 Years

    3.5.8 Diagnosed Prevalent Cases of UC by Severity for Ages ≥18 Years

    3.5.9 Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC

    3.5.10 Total Prevalent Cases of UC

    3.5.11 Age-Specific Total Prevalent Cases of UC

    3.5.12 Sex-Specific Total Prevalent Cases of UC

    3.6 Discussion

    3.6.1 Epidemiological Forecast Insight

    3.6.2 Coronavirus Disease 2019 Impact

    3.6.3 Limitations of the Analysis

    3.6.4 Strengths of the Analysis

    4 Appendix

    4.1 Bibliography

    4.2 Primary Research - Prescriber Survey

    4.3 About the Authors

    4.3.1 Epidemiologist

    4.3.2 Reviewers

    4.3.3 Global Director of Therapy Analysis and Epidemiology

    4.3.4 Global Head and EVP of Healthcare Operations and Strategy

    4.4 About GlobalData

    4.5 Contact Us

    4.6 Disclaimer

List Of Tables
in Ulcerative Colitis - Epidemiology Forecast to 2029

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for UC and IBD

Table 4: High-Prescribing Physicians (non-KOLs) Surveyed for Severity of UC for ages ≥18 years, by Country

List Of Figures, Charts and Diagrams
in Ulcerative Colitis - Epidemiology Forecast to 2029

List of Figures

Figure 1: 8MM, Diagnosed IncidentCases of UC, Both Sexes, N, All Ages ,2019 and 2029

Figure 2: 8MM, Diagnosed Prevalent Cases of UC, Both Sexes, N, All Ages ,2019 and 2029

Figure 3: 8MM, Total Prevalent Cases of UC, Both Sexes, N, All Ages,2019 and 2029

Figure 4: 8MM, Diagnosed Incidence of UC, Men and Women, Cases per 100,000 Population, All Ages, 2019

Figure 5: 8MM, Diagnosed Prevalence of UC, Men and Women, %, All Ages, 2019

Figure 6: 8MM, Total Prevalence of UC, Men and Women, %, All Ages, 2019

Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of UC

Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of UC

Figure 9: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of UC

Figure 10: 8MM, Sources Used to Forecast the Post-Operative UC Cases among Diagnosed Prevalent Cases of UC

Figure 11: 8MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of UC for Ages <18 years

Figure 12: 8MM, Diagnosed Incident Cases of UC, N, Both Sexes, All Ages, 2019

Figure 13: 8MM, Diagnosed Incident Cases of UC by Age, N, Both Sexes, 2019

Figure 14: 8MM, Diagnosed Incident Cases of UC by Sex, N, All Ages, 2019

Figure 15: 8MM, Diagnosed Prevalent Cases of UC, N, Both Sexes, All Ages, 2019

Figure 16: 8MM, Diagnosed Prevalent Cases of UC by Age, N, Both Sexes, 2019

Figure 17: 8MM, Diagnosed Prevalent Cases of UC by Sex, N, All Ages, 2019

Figure 18: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages <18 years, 2019

Figure 19: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages ≥18 Years, 2019

Figure 20: 8MM, Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC, 2019

Figure 21: 8MM, Total Prevalent Cases of UC, N, Both Sexes, All Ages, 2019

Figure22: 8MM, Total Prevalent Cases of UC by Age, N, Both Sexes, 2019

Figure 23: 8MM, Total Prevalent Cases of UC by Sex, N, All Ages, 2019

Additional Details

Publisher

Global Data

Publisher Information

Reference

274554 | GDHCER254-20

Number of Pages

58

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Ulcerative Colitis - Epidemiology Forecast to 2029 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...